New York, NY (PRWEB) March 12, 2014
The prescription drug safety center DrugRisk.com is announcing new information on the site for patients using testosterone replacement therapy drugs. A report shows the world’s largest endocrinology organization has called for new testing after studies show they may cause heart attacks or stroke*.
DrugRisk is a free resource for those using popular prescription drugs. By providing the latest warnings, safety alerts, recalls and litigation news, the site allows patients to see if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
Last year, more than 5.5 million men filled prescriptions for low-T drugs like AndroGel, Axiron and AndroDerm**. However, recent studies question their safety.
DrugRisk has added research from UCLA and the National Institutes of Health and UCLA showing those over 65 or with a history of heart disease using low-T drugs had double the rate of heart attack***. Last year, the AMA released data showing the same patients also had a 29% increased rate of heart attacks, stroke or death from low-T drugs****
Now, the world’s oldest and largest hormone and endocrinology organization, the Endocrine Society, has called for new and larger testing of testosterone drugs in order to identify safety risks*.
Patients have already filed testosterone lawsuits in federal court alleging drugs like AndroGel caused heart attack or stroke without warning*****. Lawyers are offering help to those affected.
Anyone who suffered a heart attack, stroke or cardiovascular event after using a low-T drug like AndroGel, Axiron or AndroDerm is urged to visit DrugRisk or speak with a lawyer about their legal rights as soon as possible. DrugRisk only recommends lawyers who have already handled testosterone lawsuits.
For more information on the research, side effects and litigation news related to testosterone drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Endocrine Society, 2/7/14; endocrine.org/news-room/current-press-releases/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks
**Bloomberg, 1/31/14; bloomberg.com/news/2014-01-31/heart-attack-risk-of-testosterone-drugs-under-u-s-review.html
***Public Library of Science, 1/29/14; plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0085805
****JAMA 11/5/13; media.jamanetwork.com/news-item/testosterone-therapy-following-coronary-angiography-associated-increased-risk-adverse-outcomes/
*****Bloomberg, 2/5/14; bloomberg.com/news/2014-02-05/abbott-labs-sued-by-five-men-claiming-androgel-injuries.html; Aurecchia v. AbbVie Inc., 14-cv-00772, U.S. Dist. Ct, Northern District of Illinois (Chicago); Marino v. AbbVie Inc., 14-cv-00777 U.S. Dist. Ct, Northern District of Illinois (Chicago)